BridgeBio Advances ATTR-CM Treatment with Phase 3b/4 Study
Event summary
- BridgeBio dosed the first participant in the ASCEND-ATTR Phase 3b/4 study on August 26, 2026, evaluating long-term effects of acoramidis on ATTR-CM.
- The study aims to enroll 150 participants and will run for 36 months, using CMR and echocardiography to assess cardiac structure, function, and amyloid burden.
- Previous CMR substudy data suggested acoramidis may reverse disease progression by enabling cardiac remodeling and functional recovery.
- Additional data from the ATTRibute-CM CMR substudy will be presented at the ESC Congress 2026.
The big picture
BridgeBio's ASCEND-ATTR study represents a strategic shift in ATTR-CM treatment, moving from disease progression slowing to potential reversal. The study's focus on long-term structural and functional improvements aligns with broader industry trends toward regenerative therapies and precision medicine. Success could solidify BridgeBio's leadership in genetic condition treatments, particularly in underserved patient populations.
What we're watching
- Therapeutic Potential
- Whether acoramidis can sustain long-term cardiac remodeling and functional recovery in ATTR-CM patients.
- Clinical Validation
- The pace at which ASCEND-ATTR confirms prior findings of disease regression and heart health restoration.
- Market Differentiation
- How BridgeBio positions acoramidis as the only selective small molecule TTR stabilizer in a competitive landscape.